tiprankstipranks
Advertisement
Advertisement
Actinium Pharmaceuticals receives two patent allowances from CIPO
PremiumThe FlyActinium Pharmaceuticals receives two patent allowances from CIPO
7d ago
Analyst Reiterates Buy on Actinium, Keeps $4 Price Target Amid Advancing Radiotherapy Pipeline and 2026–2027 Catalysts
Premium
Ratings
Analyst Reiterates Buy on Actinium, Keeps $4 Price Target Amid Advancing Radiotherapy Pipeline and 2026–2027 Catalysts
24d ago
Reinforced Buy on Actinium: Strengthening ATNM-400 Pan-Tumor Data and Expanding Actimab-A AML Opportunities Drive Pipeline Upside
Premium
Ratings
Reinforced Buy on Actinium: Strengthening ATNM-400 Pan-Tumor Data and Expanding Actimab-A AML Opportunities Drive Pipeline Upside
1M ago
Promising Potential of Actinium Pharmaceuticals’ ATNM-400 Drives Buy Rating
PremiumRatingsPromising Potential of Actinium Pharmaceuticals’ ATNM-400 Drives Buy Rating
6M ago
Actinium Pharmaceuticals: Promising Developments and Strong Financial Position Drive Buy Rating
Premium
Ratings
Actinium Pharmaceuticals: Promising Developments and Strong Financial Position Drive Buy Rating
6M ago
Promising Preclinical Data for ATNM-400 Reinforces Buy Rating for Actinium Pharmaceuticals
Premium
Ratings
Promising Preclinical Data for ATNM-400 Reinforces Buy Rating for Actinium Pharmaceuticals
6M ago
Actinium Pharmaceuticals: Promising Developments and Strong Financial Health Support Buy Rating
PremiumRatingsActinium Pharmaceuticals: Promising Developments and Strong Financial Health Support Buy Rating
7M ago
Actinium Pharmaceuticals: Promising Developments in Targeted Radiotherapies Drive Buy Rating
Premium
Ratings
Actinium Pharmaceuticals: Promising Developments in Targeted Radiotherapies Drive Buy Rating
7M ago
Actinium Pharmaceuticals: Promising Preclinical Success and Innovative Radiotherapy Developments Drive Buy Rating
Premium
Ratings
Actinium Pharmaceuticals: Promising Preclinical Success and Innovative Radiotherapy Developments Drive Buy Rating
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100